INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 May 2018
Net Assets |
£235m |
Net Assets per share |
626p |
Share price |
595p |
Total value of unquoted investments |
£23m |
Total number of portfolio companies |
78 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Neurocrine |
5.5 |
Celgene |
4.8 |
Biogen |
4.3 |
Vertex |
4.1 |
Array |
4.0 |
Illumina |
3.9 |
Sage |
3.9 |
Morphosys |
3.7 |
Genmab |
3.6 |
Adamas |
3.4 |
|
----------- |
Total |
41.2 |
Geographical Allocation |
% NAV |
US & Canada |
86 |
Europe |
14 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
90 |
Unquoted |
10 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
35 |
Mid Cap =USD1-10BN |
41 |
Small Cap <USD1BN |
24 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
43 |
CNS |
16 |
Rare diseases |
11 |
Inflammation |
6 |
Ophthalmology |
6 |
Infectious Diseases |
3 |
Metabolic |
3 |
Medtech |
2 |
Other |
10 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
18 JUNE 2018